Terms ending in 2042
Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,583,638 | Method for Filling Vials Containing Liquid Drug Products In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 12,358,875 | N-(PHENYL)-Indole-3-Sulfonamide Derivatives And Related Compounds As GPR17 Modulators For Treating CNS Disorders Such As Multiple Sclerosis In force · High confidence | Ucb Pharma GmbH | In force | High confidence | |
| US 12,649,754 | Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone In force · High confidence | Ucb Biopharma SRL | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.